Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients-Reference-Cited by-同舟云学术

Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients

Published:2024-02-01 Issue:Supplement_1 Volume:13 Page:S14-S21
ISSN:2048-7207
Container-title:Journal of the Pediatric Infectious Diseases Society
language:en
Short-container-title:

Author:

Valencia Deray Kristen G¹^ORCID,Danziger-Isakov Lara A²³,Downes Kevin J⁴⁵^ORCID

Affiliation:

1. Department of Pediatrics, Division of Infectious Diseases, Baylor College of Medicine , Houston, Texas , USA

2. Division of Infectious Disease, Cincinnati Children’s Hospital Medical Center , Cincinnati, Ohio , USA

3. Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio , USA

4. Division of Infectious Diseases, Children’s Hospital of Philadelphia , Philadelphia, Pennsylvania , USA

5. Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania , Philadelphia, Pennsylvania , USA

Abstract

Abstract Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.

Funder

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jpids/article-pdf/13/Supplement_1/S14/56778783/piad059.pdf

Reference85 articles.

1. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients;Deray;Am J Transplant,2022

2. CMV infection and management among pediatric solid organ transplant recipients;Downes;Pediatr Transplant,2022

3. Cytomegalovirus treatment in pediatric hematopoietic stem cell transplant patients;Wattles;J Pediatr Hematol Oncol,2017

4. American Society for Transplantation and Cellular Therapy Series: #3—Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation—ScienceDirect [Internet];Hakki

5. The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation;Kotton;Transplantation,2018